Markets

Amgen Updates Guidance - Quick Facts

(RTTNews) - Amgen (AMGN) announced, for the full year 2019, the company now expects: non-GAAP earnings per share in the range of $14.20 to $14.45. Previously, the company expected non-GAAP EPS in the range of $13.75 to $14.30. Total revenues are currently projected in the range of $22.8 billion to $23.0 billion. Previously, the company expected total revenues in the range of $22.4 billion to $22.9 billion.

Analysts polled by Thomson Reuters expect the company to report profit per share of $14.39 on revenue of $22.85 billion. Analysts' estimates typically exclude special items.

For the third-quarter, non-GAAP EPS decreased 1 percent to $3.66 as a result of lower revenue, offset partially by lower weighted-average shares outstanding. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $3.53, for the quarter.

Third-quarter total revenues decreased 3 percent to $5.7 billion in comparison to the third quarter of 2018, reflecting the impact of biosimilar and generic competition against key products. Analysts expected revenue of $5.63 billion, for the quarter. Total product sales decreased 1 percent.

Amgen expects to close the Otezla acquisition before the end of the fourth quarter.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMGN

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More